Guidelines for Infection Prophylaxis, Monitoring and Therapy in Cord Blood Transplantation.
blood transplantation
cbt
cord
infection prophylaxis
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
26
01
2021
accepted:
27
01
2021
entrez:
9
5
2021
pubmed:
10
5
2021
medline:
3
7
2021
Statut:
ppublish
Résumé
As an alternative stem cell source, cord blood (CB) has many advantages. However, delayed engraftment, lack of transferred immunity, and a significant incidence of acute graft-versus-host disease renders CB transplant (CBT) recipients at high risk of infectious complications. This guidance written by CBT and infectious disease experts outlines evidence-based recommendations for the prevention and treatment of opportunistic infections in adult patients undergoing CBT. Topics addressed include bacterial, fungal, viral, pneumocystis jirovcii and toxoplasmosis prophylaxis, suggested PCR monitoring for viruses, therapy for the most commonly encountered infections after CBT. We review key concepts including the recent important role of letermovir in the prevention of CMV reactivation. In instances where there is a paucity of data, practice recommendations are provided, including the duration of antimicrobial prophylaxis.
Identifiants
pubmed: 33965172
pii: S2666-6367(21)00633-3
doi: 10.1016/j.jtct.2021.01.024
pii:
doi:
Types de publication
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-362Informations de copyright
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.